Results from a clinical trial of eteplirsen, a drug designed to treat Duchenne muscular dystrophy, suggest that the therapy allows participants to walk farther than people treated with placebo and dramatically increases production of a protein vital to muscle growth and health.
The study, led by a team in The Research Institute at Nationwide Children’s Hospital, is the first of its kind to show these results from an exon-skipping drug—a class of therapeutics that allows cells to skip over missing parts of the gene and produce protein naturally.
“I’ve been doing this for more than 40 years and this is one of the most exciting developments we’ve seen,” says Jerry Mendell, MD, lead author of the study and director of the Center for Gene Therapy at Nationwide Children’s. “It offers great hope to patients with and their families.”
The research, which appears online Aug. 1 in the journal Annals of Neurology, is the first study from a double-blind controlled randomized trial of an exon-skipping agent to provide conclusive proof based on the standard six-minute walk test used to measure muscle function in patients with Duchenne muscular dystrophy (DMD), the most common form of muscular dystrophy in children.
About one in every 5,000 male births in the U.S. has the disorder, which usually leaves patients unable to walk on their own by age 12. Children with DMD have a mutation that cripples the body’s ability to produce a protein called dystrophin, which helps absorb the shock or energy that’s created when a muscle contracts. Without it, that released energy injures muscle fibers. Over time, the muscle degenerates, scar tissue builds up and fat slowly replaces the dead muscle.
The exact mutation varies from patient to patient but in 65 percent of cases, the dystrophin gene is missing large sections of DNA called exons, which carry the instructions for protein production. Accompanying this type of mutation is a spontaneously occurring reaction that enables muscle cells to skip over the deleted sections and produce smaller—but functional—versions of protein.
Eteplirsen, manufactured by Sarepta Therapeutics in Cambridge, Mass., mimics this naturally occurring phenomenon, allowing cells to skip over exon 51 in the dystrophin gene. About 13 percent of patients with the disorder have this mutation. Nationwide Children’s began the phase II trial of eteplirsen in August 2011, enrolling 12 boys age 7 to 12 years.
Participants received the drug via weekly IVs, with one group getting a 30 mg/kg dose and another group receiving 50 mg/kg. A control group received a placebo. Participants completed a six-minute walk test at the outset and again at weeks 12, 24 and 48. Muscle biopsies were also taken when the study began and again at those intervals to measure for dystrophin-positive muscle fibers.
Although there was no dystrophin production at 12 weeks, participants showed a 23 percent increase in dystrophin-positive muscle fibers by the 24-week mark. The striking improvement and lack of side effects prompted researchers to switch participants in the placebo group to the drug. By week 48, participants had a 52 percent increase in dystrophin-positive muscle fibers and were able to walk 67.3 meters farther than the placebo group on the six-minute walk test.
Although the results are promising, Dr. Mendell is quick to note that the small study leaves many questions unanswered.
The Latest on: Duchenne Muscular Dystrophy
- Single CRISPR treatment can safely and stably correct genetic disease on February 18, 2019 at 10:54 am
Genetic edits and protein restoration in mouse models of Duchenne muscular dystrophy remain viable one year after single CRISPR treatment Researchers at Duke University have shown that a single system... […]
- DMD: Single CRISPR treatment provides long-term benefits in mice on February 18, 2019 at 10:14 am
Researchers have shown that a single systemic treatment using CRISPR genome editing technology can safely and stably correct a genetic disease -- Duchenne muscular dystrophy (DMD) -- for more than a y... […]
- Single CRISPR treatment provides long-term benefits in mice on February 18, 2019 at 8:06 am
Researchers at Duke University have shown that a single systemic treatment using CRISPR genome editing technology can safely and stably correct a genetic disease—Duchenne muscular dystrophy (DMD ... […]
- CRISPR corrects DMD in mice for a year in Sarepta-supported study on February 18, 2019 at 8:00 am
In 2017, Duchenne muscular dystrophy drug maker Sarepta signed a deal with Duke University to research potential cures for the disease using the gene-editing system CRISPR. Now the Duke lab at the cen... […]
- New breakthroughs for muscular dystrophy research on February 15, 2019 at 6:45 am
One step along the chain Vidal-Gadea's team examined was the amount of calcium released in the muscles of those battling Duchenne muscular dystrophy. "There is a build-up of calcium that is ... […]
- PTC Therapeutics Launches Fifth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy on February 13, 2019 at 5:00 am
SOUTH PLAINFIELD, N.J., Feb. 13, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. PTCT, +1.74% today announced the launch of the fifth annual STRIVE grant award program for Duchenne Muscular Dystrophy. The ... […]
- URMC Designated as a Duchenne Care Center on February 11, 2019 at 12:14 pm
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization dedicated to advancing care and research for patients with Duchenne muscular dystrophy, has named the University of Rochester Medical ... […]
- Parent Project Muscular Dystrophy Designates University of Rochester Medical Center as a Certified Duchenne Care Center on February 11, 2019 at 7:23 am
HACKENSACK, N.J., Feb. 11, 2019 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), named the University ... […]
- A Setback for Solid Is a Win for Sarepta in Race to Treat Muscular Dystrophy on February 7, 2019 at 9:47 am
Sarepta Therapeutics (ticker: SRPT) has solidified its position as the leader in the development of a gene therapy for Duchenne muscular dystrophy following disappointing data from a clinical trial re... […]
- Solid Biosciences to soldier on as initial muscular dystrophy gene therapy results disappoint on February 7, 2019 at 3:47 am
Ilan Ganot, the co-founder and chief executive of biotech firm Solid Biosciences, left a career in investment banking to start the company in 2013 in order to search for treatments, and perhaps cures, ... […]
via Google News and Bing News